Patents by Inventor Jean-Claude Mazie

Jean-Claude Mazie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDES OF IL-2
    Publication number: 20100273723
    Abstract: The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents.
    Type: Application
    Filed: January 21, 2010
    Publication date: October 28, 2010
    Applicant: INSTITUT PASTEUR
    Inventors: Jacques Theze, Ralph Eckenberg, Jean-Louis Moreau, Michel Goldberg, Thierry Rose, Pedro Alzari, Jean-Claude Mazie
  • Method for inducing selected useful activities of IL-2 in a patient with peptides from IL-2
    Patent number: 7704490
    Abstract: The present invention relates to new peptides of IL-2, and derivatives thereof and their use as therapeutic agents.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: April 27, 2010
    Assignee: Institut Pasteur
    Inventors: Jacques Theze, Ralph Eckenberg, Jean-Louis Moreau, Michel Goldberg, Thierry Rose, Pedro Alzari, Jean-Claude Mazie
  • Method of inducing SHC phosphorylation of inducing the SHC/MAPK pathway by administering a peptide of IL-2
    Patent number: 7662368
    Abstract: The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: February 16, 2010
    Assignee: Institut Pasteur
    Inventors: Jacques Theze, Ralph Eckenberg, Jean-Louis Moreau, Michel Goldberg, Thierry Rose, Pedro Alzari, Jean-Claude Mazie
  • Peptides of IL-2
    Publication number: 20070048302
    Abstract: The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents.
    Type: Application
    Filed: July 28, 2006
    Publication date: March 1, 2007
    Applicant: INSTITUT PASTEUR
    Inventors: Jacques Theze, Ralph Eckenberg, Jean-Louis Moreau, Michel Golberg, Thierry Rose, Pedro Alzari, Jean-Claude Mazie
  • Therapeutic composition comprising the KAL protein and use of the KAL protein for the treatment of retinal, renal, neuronal and neural injury
    Publication number: 20070037736
    Abstract: KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.
    Type: Application
    Filed: June 29, 2006
    Publication date: February 15, 2007
    Applicants: INSTITUT PASTEUR, Centre National De La Recherche Scient.
    Inventors: Christine Petit, Nadia Soussi-Yanicostas, Jean-Pierre Hardelin, Catherine Sarailh, Genevieve Rougon, Renaud Legouis, Olivier Ardouin, Jean-Claude Mazie
  • Peptides of IL-2
    Patent number: 7101965
    Abstract: The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: September 5, 2006
    Assignee: Institut Pasteur
    Inventors: Jacques Theze, Ralph Eckenberg, Jean-Louis Moreau, Michel Goldberg, Thierry Rose, Pedro Alzari, Jean-Claude Mazie
  • Peptides of IL-2 and derivatives thereof and their use as therapeutic agents
    Publication number: 20060018873
    Abstract: The present invention relates to new peptides of IL-2, and derivatives thereof and their use as therapeutic agents.
    Type: Application
    Filed: June 28, 2005
    Publication date: January 26, 2006
    Applicant: INSTITUT PASTEUR
    Inventors: Jacques Theze, Ralph Eckenberg, Jean-Louis Moreau, Michel Goldberg, Thierry Rose, Pedro Alzari, Jean-Claude Mazie
  • Peptides of IL-2 and derivatives thereof
    Patent number: 6929791
    Abstract: The present invention relates to new peptides of IL-2, and derivatives thereof and their use as therapeutic agents.
    Type: Grant
    Filed: February 6, 2001
    Date of Patent: August 16, 2005
    Assignee: Institut Pasteur
    Inventors: Jacques Theze, Ralph Eckenberg, Jean-Louis Moreau, Michel Goldberg, Thierry Rose, Pedro Alzari, Jean-Claude Mazie
  • Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof
    Publication number: 20050019826
    Abstract: The present invention provides peptides which can interact with VEGF and inhibit VEGF interaction with KDR or anti-VEGF antibody thereby inhibiting VEGF mediated angiogenesis or angiogeneis related diseases, polynucleotide encoding the peptides, vectors containing the polynucleotides, pharmaceutical compositions containing the peptides, and methods of inhibiting angiogenesis with the peptides.
    Type: Application
    Filed: March 29, 2001
    Publication date: January 27, 2005
    Inventors: Roselyne Tournaire, Caroline Demangel, Claude Derbin, Gerard Perret, Jean-Claude Mazie, Jean Plouet, Roger Vassy
  • Peptides of IL-2 and derivatives thereof and their use as therapeutic agents
    Patent number: 6825334
    Abstract: The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: November 30, 2004
    Assignee: Institut Pasteur
    Inventors: Jacques Theze, Ralph Eckenberg, Jean-Louis Moreau, Michel Golberg, Thierry Rose, Pedro Alzari, Jean-Claude Mazie
  • Peptides of IL-2 and derivatives thereof and their use as therapeutic agents
    Publication number: 20040202661
    Abstract: The present invention relates to new peptides of IL-2, derivatives thereof, and their use as therapeutic agents.
    Type: Application
    Filed: December 5, 2003
    Publication date: October 14, 2004
    Applicant: INSTITUT PASTEUR
    Inventors: Jacques Theze, Ralph Eckenberg, Jean-Louis Moreau, Michel Golberg, Thierry Rose, Pedro Alzari, Jean-Claude Mazie
  • Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury
    Patent number: 6770743
    Abstract: KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: August 3, 2004
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Christine Petit, Nadia Soussi-Yanticostas, Jean-Pierre Hardelin, Catherine Sarailh, Genevieve Rougon, Renaud Legouis, Olivier Ardouin, Jean-Claude Mazie
  • Peptides blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
    Publication number: 20030171289
    Abstract: The present invention provides peptides which can interact with VEGF and inhibit VEGF interaction with KDR or anti-VEGF antibody thereby inhibiting VEGF mediated angiogenesis or angiogeneis related diseases, polynucleotide encoding the peptides, vectors containing the polynucleotides, pharmaceutical compositions containing the peptides, and methods of inhibiting angiogenesis with the peptides.
    Type: Application
    Filed: January 15, 2003
    Publication date: September 11, 2003
    Applicant: INSTITUT PASTEUR
    Inventors: Roselyne Tournaire, Caroline Demangel, Claude Derbin, Gerard Perret, Jean-Claude Mazie, Jean Plouet, Roger Vassy
  • DNA encoding peptides of IL-2
    Patent number: 6596853
    Abstract: The invention relates to the use as therapeutic agents of IL-2 peptides and derivatives having biological activity and anti-IL-2 antibodies which mimic or modulate the biological activities of IL-2. The invention also relates to DNA sequences encoding the IL-2 peptides, and to methods of using the IL-2 peptides and derivatives and anti-IL-2 antibodies to modulate or mimic or antagonize the biological activities of IL-2 in vivo and to assay for the presence and activity of the IL-2 receptor.
    Type: Grant
    Filed: September 12, 2000
    Date of Patent: July 22, 2003
    Assignee: Institut Pasteur
    Inventors: Jacques Theze, Ralph Eckenberg, Jean-Louis Moreau, Jean-Claude Mazie
  • Peptides blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
    Patent number: 6559126
    Abstract: The present invention provides peptides which can interact with VEGF and inhibit VEGF interaction with KDR or anti-VEGF antibody thereby inhibiting VEGF mediated angiogenesis or angiogeneis related diseases, polynucleotide encoding the peptides, vectors containing the polynucleotides, pharmaceutical compositions containing the peptides, and methods of inhibiting angiogenesis with the peptides.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: May 6, 2003
    Assignee: Institut Pasteur
    Inventors: Roselyne Tournaire, Caroline Demangel, Claude Derbin, Gerard Perret, Jean-Claude Mazie, Jean Plouet, Roger Vassy
  • Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury
    Patent number: 6548475
    Abstract: KAL protein is identified as the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: April 15, 2003
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Christine Petit, Nadia Soussi-Yanticostas, Jean-Pierre Hardelin, Catherine Sarailh, Genevieve Rougon, Renaud Legouis, Olivier Ardouin, Jean-Claude Mazie
  • Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury
    Publication number: 20030060401
    Abstract: KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.
    Type: Application
    Filed: August 16, 2002
    Publication date: March 27, 2003
    Applicant: INSTITUT PASTEUR
    Inventors: Christine Petit, Nadia Soussi-Yanticostas, Jean-Pierre Hardelin, Catherine Sarailh, Genevieve Rougon, Renaud Legouis, Olivier Ardouin, Jean-Claude Mazie
  • Therapeutic composition comprising the KAL protein and use of the KAL protein for the treatment of retinal, renal, neuronal and neural injury
    Publication number: 20020123467
    Abstract: KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.
    Type: Application
    Filed: April 11, 2002
    Publication date: September 5, 2002
    Applicant: INSTITUT PASTEUR
    Inventors: Christine Petit, Nadia Soussi-Yanicostas, Jean-Pierre Hardelin, Catherine Sarailh, Genevieve Rougon, Renaud Legouis, Olivier Ardouin, Jean-Claude Mazie
  • Peptides blocking vascular endothelial growth factor (VEGF) -mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
    Publication number: 20020068697
    Abstract: The present invention provides peptides which can interact with VEGF and inhibit VEGF interaction with KDR or anti-VEGF antibody thereby inhibiting VEGF mediated angiogenesis or angiogeneis related diseases, polynucleotide encoding the peptides, vectors containing the polynucleotides, pharmaceutical compositions containing the peptides, and methods of inhibiting angiogenesis with the peptides.
    Type: Application
    Filed: April 2, 2001
    Publication date: June 6, 2002
    Inventors: Roselyne Tournaire, Caroline Demangel, Claude Derbin, Gerard Perret, Jean-Claude Mazie, Jean Plouet, Roger Vassy
  • Peptides of IL-2 and derivatives thereof and their use as therapeutic agents
    Publication number: 20020044935
    Abstract: The present invention relates to new peptides of IL-2, and derivatives thereof and their use as therapeutic agents.
    Type: Application
    Filed: February 6, 2001
    Publication date: April 18, 2002
    Applicant: INSTITUT PASTEUR
    Inventors: Jacques Theze, Ralph Eckenberg, Jean-Louis Moreau, Michel Goldberg, Thierry Rose, Pedro Alzari, Jean-Claude Mazie